Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Monoclonal antibodies against pools of mono- and polyacetylated peptides selectively recognize acetylated lysines within the context of the original antigen.

Sandomenico A, Focà A, Sanguigno L, Caporale A, Focà G, Pignalosa A, Corvino G, Caragnano A, Beltrami AP, Antoniali G, Tell G, Leonardi A, Ruvo M.

MAbs. 2016 Nov/Dec;8(8):1575-1589. Epub 2016 Aug 25.

2.

The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sezary Syndrome Alone or with Doxorubicin.

Moyal L, Feldbaum N, Goldfeiz N, Rephaeli A, Nudelman A, Weitman M, Tarasenko N, Gorovitz B, Maron L, Yehezkel S, Amitay-Laish I, Lubin I, Hodak E.

PLoS One. 2016 Jan 11;11(1):e0146115. doi: 10.1371/journal.pone.0146115. eCollection 2016.

3.

In silico pathway analysis in cervical carcinoma reveals potential new targets for treatment.

van Dam PA, van Dam PJ, Rolfo C, Giallombardo M, van Berckelaer C, Trinh XB, Altintas S, Huizing M, Papadimitriou K, Tjalma WA, van Laere S.

Oncotarget. 2016 Jan 19;7(3):2780-95. doi: 10.18632/oncotarget.6667.

4.

A structure-activity relationship of non-peptide macrocyclic histone deacetylase inhibitors and their anti-proliferative and anti-inflammatory activities.

Tapadar S, Fathi S, Raji I, Omesiete W, Kornacki JR, Mwakwari SC, Miyata M, Mitsutake K, Li JD, Mrksich M, Oyelere AK.

Bioorg Med Chem. 2015 Dec 15;23(24):7543-64. doi: 10.1016/j.bmc.2015.10.045. Epub 2015 Nov 2.

5.

Current and future treatment options for polycythemia vera.

Griesshammer M, Gisslinger H, Mesa R.

Ann Hematol. 2015 Jun;94(6):901-10. doi: 10.1007/s00277-015-2357-4. Epub 2015 Apr 2. Review.

6.

NL-103, a novel dual-targeted inhibitor of histone deacetylases and hedgehog pathway, effectively overcomes vismodegib resistance conferred by Smo mutations.

Zhao J, Quan H, Xie C, Lou L.

Pharmacol Res Perspect. 2014 Jun;2(3):e00043. doi: 10.1002/prp2.43. Epub 2014 Apr 7.

7.

HDAC4 degradation mediates HDAC inhibition-induced protective effects against hypoxia/reoxygenation injury.

Du J, Zhang L, Zhuang S, Qin GJ, Zhao TC.

J Cell Physiol. 2015 Jun;230(6):1321-31. doi: 10.1002/jcp.24871.

8.

Histone deacetylase inhibitors modulate miRNA and mRNA expression, block metaphase, and induce apoptosis in inflammatory breast cancer cells.

Chatterjee N, Wang WL, Conklin T, Chittur S, Tenniswood M.

Cancer Biol Ther. 2013 Jul;14(7):658-71. doi: 10.4161/cbt.25088. Epub 2013 Jun 24.

9.

HDAC inhibition elicits myocardial protective effect through modulation of MKK3/Akt-1.

Zhao TC, Du J, Zhuang S, Liu P, Zhang LX.

PLoS One. 2013 Jun 10;8(6):e65474. doi: 10.1371/journal.pone.0065474. Print 2013. Erratum in: PLoS One. 2013;8(7). doi:10.1371/annotation/29be7977-2e22-40cd-8a71-b3fbb99de9d5. Zhuang, Shugang [corrected to Zhuang, Shougang].

10.

Inhibition of histone deacetylase-induced myocardial repair is mediated by c-kit in infarcted hearts.

Zhang L, Chen B, Zhao Y, Dubielecka PM, Wei L, Qin GJ, Chin YE, Wang Y, Zhao TC.

J Biol Chem. 2012 Nov 16;287(47):39338-48. doi: 10.1074/jbc.M112.379115. Epub 2012 Sep 28.

11.

Inhibition of histone deacetylases preserves myocardial performance and prevents cardiac remodeling through stimulation of endogenous angiomyogenesis.

Zhang L, Qin X, Zhao Y, Fast L, Zhuang S, Liu P, Cheng G, Zhao TC.

J Pharmacol Exp Ther. 2012 Apr;341(1):285-93. doi: 10.1124/jpet.111.189910. Epub 2012 Jan 23.

12.

HDAC inhibition promotes cardiogenesis and the survival of embryonic stem cells through proteasome-dependent pathway.

Chen HP, Denicola M, Qin X, Zhao Y, Zhang L, Long XL, Zhuang S, Liu PY, Zhao TC.

J Cell Biochem. 2011 Nov;112(11):3246-55. doi: 10.1002/jcb.23251.

13.

Non-peptide macrocyclic histone deacetylase inhibitors derived from tricyclic ketolide skeleton.

Mwakwari SC, Guerrant W, Patil V, Khan SI, Tekwani BL, Gurard-Levin ZA, Mrksich M, Oyelere AK.

J Med Chem. 2010 Aug 26;53(16):6100-11. doi: 10.1021/jm100507q.

14.

gp-91 mediates histone deacetylase inhibition-induced cardioprotection.

Zhao TC, Zhang LX, Cheng G, Liu JT.

Biochim Biophys Acta. 2010 Jul;1803(7):872-80. doi: 10.1016/j.bbamcr.2010.04.007. Epub 2010 Apr 28.

15.

Chemopreventive mechanisms of α-keto acid metabolites of naturally occurring organoselenium compounds.

Pinto JT, Lee JI, Sinha R, MacEwan ME, Cooper AJ.

Amino Acids. 2011 Jun;41(1):29-41. doi: 10.1007/s00726-010-0578-3. Epub 2010 Apr 10. Review.

16.

Targeted deletion of NF-kappaB p50 diminishes the cardioprotection of histone deacetylase inhibition.

Zhang LX, Zhao Y, Cheng G, Guo TL, Chin YE, Liu PY, Zhao TC.

Am J Physiol Heart Circ Physiol. 2010 Jun;298(6):H2154-63. doi: 10.1152/ajpheart.01015.2009. Epub 2010 Apr 9.

17.

Anti-leukemia activity of MS-275 histone deacetylase inhibitor implicates 4-1BBL/4-1BB immunomodulatory functions.

Vire B, de Walque S, Restouin A, Olive D, Van Lint C, Collette Y.

PLoS One. 2009 Sep 17;4(9):e7085. doi: 10.1371/journal.pone.0007085.

18.

Pharmacodynamic assessment of histone deacetylase inhibitors: infrared vibrational spectroscopic imaging of protein acetylation.

Chen T, Lee MJ, Kim YS, Lee S, Kummar S, Gutierrez M, Hewitt SM, Trepel JB, Levin IW.

Anal Chem. 2008 Aug 15;80(16):6390-6. doi: 10.1021/ac800840y. Epub 2008 Jul 24.

19.

Role of retinoic receptors in lung carcinogenesis.

Bogos K, Renyi-Vamos F, Kovacs G, Tovari J, Dome B.

J Exp Clin Cancer Res. 2008 Jul 14;27:18. doi: 10.1186/1756-9966-27-18. Review.

20.

Supplemental Content

Support Center